‘Moana 2’ tops $1 billion, extending Disney’s box office domination
[#item_full_content]
J&J beats quarterly sales and profit estimates on cancer drug sales
By Patrick Wingrove and Bhanvi Satija (Reuters) -Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments. The
J&J tops earnings estimates amid strong demand for cancer treatments
Investing.com – Johnson & Johnson (NYSE:JNJ) posted fourth-quarter adjusted earnings and sales that topped analysts’ estimates, as the pharmaceutical firm was boosted by demand for its cancer treatments. The drugmaker added that it now expects to deliver full-year sales of $90.9 billion